Respiratory syncytial virus vaccine, adjuvanted is an adjuvanted respiratory syncytial virus vaccine in older adults. It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with the accompanying vial of AS01E adjuvant as the...
- Mechanism
- Curator reviewed · 3 references
Respiratory tract infections caused by RSV can be severe in high-risk populations, such as infants and elderly patients. Immunization remains one of the key preventative measures against RSV infection.
GSK-3844766A is an adjuvanted vaccine consisting of an antigen (RSVPreF3), which induces a CD4 T cell response against RSV glycoprotein F stabilized in pre-fusion conformation, and the AS01E adjuvant, which stabilizes the antigen.
- Primary indication
- Arexvy is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older by the FDA and Health Canada.Curator reviewed · 5 structured indications
- First approval
- Canada, 2023 · United States, 2023
- Brand names
Resolves to
What you can answer from here — as of April 01, 2026
Which other approved drugs treat the same conditions as Respiratory syncytial virus vaccine, adjuvanted, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account